CN108403715A - Antitumor medicine composition and application thereof - Google Patents
Antitumor medicine composition and application thereof Download PDFInfo
- Publication number
- CN108403715A CN108403715A CN201810226420.XA CN201810226420A CN108403715A CN 108403715 A CN108403715 A CN 108403715A CN 201810226420 A CN201810226420 A CN 201810226420A CN 108403715 A CN108403715 A CN 108403715A
- Authority
- CN
- China
- Prior art keywords
- qinghaosu
- derivative
- iron
- medicine composition
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/26—Iron; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of antitumor medicine composition, described pharmaceutical composition includes at least one qinghaosu and its derivative, at least one iron preparation and ascorbic acid.The ascorbic acid and the iron preparation is added in antitumor medicine composition provided by the invention in the qinghaosu and its derivative, can dramatically increase the anti-tumor effect of qinghaosu and its derivative, inhibits drug resistance phenomenon.Provided by the present invention for treating the pharmaceutical composition of tumour, it can both enhance antitumor drug effect, the dosage of qinghaosu and its derivative be reduced, to reduce qinghaosu and its derivative toxicity and drug resistance to cell.
Description
Technical field
The invention belongs to field of medicinal compositions more particularly to a kind of medical composition and its uses of antitumor drug.
Background technology
(such as dihydroartemisinine, Artesunate etc. contain the sesquiterpenoids of interior peroxide bridge structure for qinghaosu and its derivative
Close object) clinic is a kind of preferable anti-malaria medicaments of curative effect, meanwhile, qinghaosu and its derivative have antitumor action.Using
Qinghaosu and its derivative have the advantages that Antitumor test is wide as antitumor drug, can be widely used for include but not limited to
The treatment of the Several Kinds of Malignancy such as osteocarcinoma, liver cancer, gastric cancer, the cancer of the esophagus, colorectal cancer, leukaemia.But using qinghaosu and its spread out
Biology still has deficiency, and preferably anti-swell could be had under higher dosage by being mainly manifested in qinghaosu and its derivative needs
The effect of tumor.In addition, the sesquiterpenoids containing interior peroxide bridge structure such as qinghaosu and its derivative such as dihydroartemisinine, Artesunate
There is phenomena such as drug resistance during antitumor in compound, and which has limited qinghaosu and its derivative clinically antitumor effects
It answers.
Invention content
The purpose of the present invention is to provide a kind of medical composition and its uses of antitumor drug, it is intended to solve qinghaosu
And its derivative needs could have preferably antitumor effect under higher dosage, and the problem of will produce drug resistance.
For achieving the above object, the technical solution adopted by the present invention is as follows：
One aspect of the present invention provides a kind of antitumor medicine composition, and described pharmaceutical composition includes at least one sweet wormwood
Element and its derivative, at least one iron preparation and ascorbic acid.
Preferably, the qinghaosu and its derivative select qinghaosu, dihydroartemisinine, Artesunate, Artemtherin, blueness
Artemisin ether.
Preferably, the iron preparation is inorganic iron.
It is further preferred that the iron preparation is selected from ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrum citricum
Ammonium, iron-dextrin, ferric oxide nanometer particle, carboxyl maltose iron, Superparamagnetic Iron Oxide.
Preferably, the qinghaosu and its derivative, ascorbic acid and iron preparation molar ratio be 1:100~1000:0.5
~10.
Preferably, further include pharmaceutically acceptable auxiliary material.
Preferably, described pharmaceutical composition is by least one qinghaosu and its derivative, at least one iron preparation, Vitamin C
Sour and pharmaceutically acceptable auxiliary material is made.
And the antitumor medicine composition is as the purposes for preparing antitumor drug.
Preferably, described pharmaceutical composition is preparing liver-cancer medicine, liver-cancer medicine, colon cancer drug, oesophagus cancer drug, lung
The purposes of cancer drug, osteocarcinoma drug.
Antitumor medicine composition provided by the invention, containing including at least one qinghaosu and its derivative, at least
A kind of iron preparation and ascorbic acid.After the qinghaosu and its derivative and the iron preparation are compound, the iron preparation enters body
After interior, the thermophilic iron characteristic of tumour cell can dramatically increase the Fe in tumour cell body2+Content, on the one hand, Fe2+It is catalyzed qinghaosu
And its peroxide bridge cleavage activity structure in derivative, promote the antitumor action of qinghaosu and its derivative；On the other hand, Fe2+
Fenton's reaction is participated in, ROS is further generated, and then inhibit intracellular GSH antioxidant systems, breaks Redox homeostasis, it will be thin
The ROS of intracellular maintains higher level.ROS can not only be damaged with lipid generation peroxidatic reaction of lipid generation lipid ROS, ROS
Hinder lipid and protein, but also DNA damage can be caused, promotes the death of cell.Qinghaosu and its derivative are assisted with iron preparation
With after, endocellular liberation iron can generate ROS with intracellular peroxidation object, and oxidat ion damage main function is suppression
Free iron processed forms ROS with intracellular peroxidation object, and qinghaosu promotes intracellular peroxidation object to generate, and inhibits glutathione oxidation
Also original system, and iron preparation promotes endocellular liberation iron to increase, and further promotes intracellular ROS to increase, inducing cell death.Into
One step, on this basis, ascorbic acid is added, on the one hand can protect normal cell oxidative damage, on the other hand, for swollen
Oncocyte can accelerate the failure tumour cell internal oxidition reduction balance, induce tumour cell oxidative stress, promote qinghaosu and its
The anti-tumor effect of derivative.To sum up, the ascorbic acid and the iron preparation are added in the qinghaosu and its derivative,
The anti-tumor effect of qinghaosu and its derivative can be dramatically increased, drug resistance phenomenon is inhibited.Provided by the present invention for treating tumour
Pharmaceutical composition, can both enhance antitumor drug effect, the dosage of qinghaosu and its derivative be reduced, to reduce qinghaosu
And its derivative is to the toxicity and drug resistance of cell.
Antitumor drug is prepared using the antitumor medicine composition, can be used for inhibiting the life of tumour cell
It is long, and inhibit the transfer of tumour.
Description of the drawings
Fig. 1 is the pharmaceutical composition of various concentration DHA and FAC provided in an embodiment of the present invention to MG-63 cell viability shadows
Ring result figure；
Fig. 2 is the pharmaceutical composition of various concentration DHA and FAC provided in an embodiment of the present invention to MNNG/HOS cell viabilities
Influence result figure；
Fig. 3, which is the pharmaceutical composition of various concentration DHA and FAC provided in an embodiment of the present invention, influences U2OS cell viabilities
Result figure；
Fig. 4 is the various concentration FAC that comparative example 2 provides influences result figure to MG-63 cell viabilities；
Fig. 5 is the various concentration FAC that comparative example 2 provides influences result figure to MNNG/HOS cell viabilities；
Fig. 6 is the various concentration FAC that comparative example 2 provides influences result figure to U2OS cell viabilities.
Specific implementation mode
In order to make technical problems, technical solutions and advantageous effects to be solved by the present invention be more clearly understood, below in conjunction with
Embodiment, the present invention will be described in further detail.It should be appreciated that specific embodiment described herein is only used to explain
The present invention is not intended to limit the present invention.
In the description of the present invention, it is to be understood that, term " first ", " second " are used for description purposes only, and cannot
It is interpreted as indicating or implies relative importance or implicitly indicate the quantity of indicated technical characteristic.Define as a result, " the
One ", the feature of " second " can explicitly or implicitly include one or more this feature.In the description of the present invention,
The meaning of " plurality " is two or more, unless otherwise specifically defined.
An embodiment of the present invention provides a kind of antitumor medicine composition, described pharmaceutical composition includes at least one green
Artemisin and its derivative, at least one iron preparation and ascorbic acid.
Antitumor medicine composition provided in an embodiment of the present invention, it includes at least one qinghaosu and its derivative to contain
Object, at least one iron preparation and ascorbic acid.After the qinghaosu and its derivative and the iron preparation are compound, the iron preparation
Into after in vivo, the thermophilic iron characteristic of tumour cell can dramatically increase the Fe in tumour cell body2+Content, on the one hand, Fe2+Catalysis
Peroxide bridge cleavage activity structure in qinghaosu and its derivative promotes the antitumor action of qinghaosu and its derivative；Another party
Face, Fe2+Fenton's reaction is participated in, ROS is further generated, and then inhibit intracellular GSH antioxidant systems, it is steady to break redox
Intracellular ROS is maintained higher level by state.ROS can occur peroxidatic reaction of lipid with lipid and generate lipid ROS, ROS
Lipid and protein are not only damaged, but also DNA damage can be caused, promotes the death of cell.Qinghaosu and its derivative and iron
After preparation collaboration, endocellular liberation iron can generate ROS with intracellular peroxidation object, and oxidat ion damage is mainly made
With being that free iron is inhibited to form ROS with intracellular peroxidation object, qinghaosu promotes intracellular peroxidation object to generate, and inhibits gluathione
Peptide oxidation-reduction system, and iron preparation promotes endocellular liberation iron to increase, and further promotes intracellular ROS to increase, inducing cell
It is dead.Further, on this basis, ascorbic acid is added, on the one hand can protect normal cell oxidative damage, another party
Face can accelerate the failure tumour cell internal oxidition reduction balance for tumour cell, induce tumour cell oxidative stress, promote green
The anti-tumor effect of artemisin and its derivative.To sum up, the ascorbic acid and institute are added in the qinghaosu and its derivative
Iron preparation is stated, the anti-tumor effect of qinghaosu and its derivative can be dramatically increased, inhibits drug resistance phenomenon.The embodiment of the present invention provides
For treating the pharmaceutical composition of tumour, can both enhance antitumor drug effect, reduce the dosage of qinghaosu and its derivative,
To reduce qinghaosu and its derivative toxicity and drug resistance to cell.
Specifically, in the embodiment of the present invention, the qinghaosu and its derivative select qinghaosu with anti-tumor activity
And its derivative, it is preferred that the qinghaosu and its derivative are selected from qinghaosu, dihydroartemisinine, Artesunate, qinghaosu first
Ether, qinghaosu ether, but not limited to this.The preferred qinghaosu and its derivative, not only compared with other qinghaosus and its derivative
Object has better antitumor activity, it is often more important that, the qinghaosu and its derivative and iron preparation, ascorbic acid is compound makes
With rear, can preferably act synergistically, the iron preparation, ascorbic acid auxiliary under, preferably play antitumor activity, drop
Low effective dose.In the antitumor medicine composition, one kind in above-mentioned qinghaosu and its derivative can be contained, also may be used
With containing a variety of in above-mentioned qinghaosu and its derivative.
The qinghaosu and its derivative have certain antitumor activity, but it is antitumor when active dose it is bigger, together
When will produce drug resistance.In view of this, the embodiment of the present invention is added to iron preparation and anti-bad in the qinghaosu and its derivative
Hematic acid.
Wherein, described iron preparation itself is without antitumor activity, but can be converted into Fe in vivo2+, on the one hand, Fe2+
It is catalyzed peroxide bridge cleavage activity structure in qinghaosu and its derivative, promotes the antitumor action of qinghaosu and its derivative；Separately
On the one hand, Fe2+The generation that Fenton's reaction promotes ROS is participated in, and then by inhibiting intracellular GSH antioxidant systems, is broken original
Qinghaosu and its Redox homeostasis that is formed of derivative, intracellular ROS is maintained into higher level, it is thin to promote
The death of born of the same parents.For the embodiment of the present invention by supplementing iron preparation, making can Fe in tumour cell2+Content increases, and is produced by Fenton's reaction
Raw a large amount of active oxygen radicals；Meanwhile the qinghaosu and its derivative can inhibit the GSH antioxidant systems in tumour cell,
Prevent the ROS generated into the cell from effectively being removed, the accumulation of ROS, the two synergistic effect is caused to promote tumour cell dead
It dies.
Preferably, the iron preparation is inorganic iron, and compared to Organic Iron, not only human body can effectively be inhaled the inorganic iron
It receives, moreover, can be by blood-brain barrier, to play its effect.Specific preferred, the iron preparation selects the benefit of clinical medical
Iron preparation.It is further preferred that the iron preparation is selected from ferrous sulfate, ferrous fumarate, ferrous gluconate, ferrum citricum
Ammonium, iron-dextrin, ferric oxide nanometer particle, carboxyl maltose iron, Superparamagnetic Iron Oxide, but not limited to this.Preferred institute
Iron preparation is stated, not only there is preferable biological safety, other security risks of human body, and the preferred iron will not be increased
Preparation has preferable bio-dissipative in human body, can effectively improve internal Fe2+Content.
Important component of the ascorbic acid as antineoplastic pharmaceutical compositions described in the embodiment of the present invention, large dosage of is anti-
After bad hematic acid enters tumor tissues, tumour cell internal oxidition Free Radical Level can be caused to increase, inducing death of neoplastic cells, simultaneously
Qinghaosu enters the intracellular tumour cell internal oxidition Free Radical Level that also can induce and increases, and the two plays synergistic antitumor effect.
Preferably, the qinghaosu and its derivative, ascorbic acid and iron preparation molar ratio be 1:100~1000:0.5~10.Institute
State that ascorbic acid content is excessively high easily to cause toxic reaction, it is too low, antioxidation is played, oncotherapy is unfavorable for.If the iron
The content of preparation is too low, is not only difficult to be catalyzed qinghaosu and its derivative, it is also difficult to intracellular ROS contents are effectively improved, from
And cannot obviously break the Redox homeostasis that original qinghaosu and its derivative are formed, qinghaosu and its derivative are resisted
Tumour does not have apparent facilitation.If the molar content of the iron preparation is excessively high, in human body, iron content is excessively high easily causes
Liver renal toxicity.It is furthermore preferred that the mole of the iron preparation accounts for the 50- of qinghaosu and its derivative and iron preparation integral molar quantity
100000%.
Pharmaceutically acceptable dosage form can be made in antitumor medicine composition described in the embodiment of the present invention.In view of
This, further, on the basis of the above embodiments, antitumor medicine composition described in the embodiment of the present invention further includes pharmacy
Upper acceptable auxiliary material.Pharmaceutically acceptable auxiliary material does not limit strictly described in the embodiment of the present invention, can be according to being made
Different dosage forms be adjusted.Specific preferred, described pharmaceutical composition is by least one qinghaosu and its derivative, at least one
Kind iron preparation, ascorbic acid and pharmaceutically acceptable auxiliary material are made.
And an embodiment of the present invention provides the antitumor medicine compositions as the use for preparing antitumor drug
On the way.Antitumor drug is prepared using the antitumor medicine composition, can be used for inhibiting the growth of tumour cell, and is pressed down
The transfer of tumour processed.Wherein, described pharmaceutical composition is preparing liver-cancer medicine, liver-cancer medicine, colon cancer drug, cancer of the esophagus medicine
The purposes of object, lung-cancer medicament, osteocarcinoma drug.
It is illustrated with reference to specific embodiment.
Embodiment 1
A kind of inhibiting effect of antineoplastic pharmaceutical compositions to osteosarcoma cell
Cell strain and cell culture：Experiment cell used includes osteosarcoma cell MG-63, MNNG/HOS and U2OS.It is all
The condition of culture of cell is：37 DEG C in carbon dioxide incubator, saturated humidity, carbon dioxide content 5%, it is grown on and contains
10% fetal calf serum, containing in 1% dual anti-DMEM culture mediums, MG-63 and MNNG/HOS passages in every two days are primary, and U2OS is every
Passage in four days is primary, and centre changes the liquid once.
The cell in logarithmic phase growth is collected, is prepared into 5 × 104The single cell suspension of a/mL.Cell suspension is pressed per hole
100uL is inoculated in 96 well culture plates, after being cultivated for 24 hours in carbon dioxide incubator, discards original fluid.It is added containing difference
Six holes, culture is arranged in the culture medium of concentration dihydroartemisinine (DHA, 0-1280uM) and 100uM Ferric Ammonium Citrates, each concentration
For 24 hours, observation drug is to cell growth effect.Non- dosing cell blank control group is separately set in experiment.Drug pair is detected with CCK-8 methods
The half-inhibition concentration of cell growth.
Comparative example 1
Growth inhibition effect of the dihydroartemisinine to tumour cell
Cell strain and cell culture are same as Example 1：Experiment cell used includes osteosarcoma cell MG-63, MNNG/
HOS and U2OS.The condition of culture of all cells is：37 DEG C in carbon dioxide incubator, saturated humidity, carbon dioxide content be
5%, it is grown on containing 10% fetal calf serum, containing in 1% dual anti-DMEM culture mediums, MG-63 and MNNG/HOS are passed for every two days
In generation, is primary, and U2OS passages in every four days are primary, and centre changes the liquid once.
The cell in logarithmic phase growth is collected, the single cell suspension of 5 × 104/mL is prepared into.Cell suspension is pressed per hole
100uL is inoculated in 96 well culture plates, after being cultivated for 24 hours in carbon dioxide incubator, discards original fluid.It is added containing difference
Concentration dihydroartemisinine to be measured (0uM, 1uM, 2uM, 4uM, 16uM, 32uM, 64uM and 128uM)) culture medium, each concentration sets
Set six holes, cultivate respectively for 24 hours, 48h, 72h, effect of the observation drug to osteosarcoma cell.Non- dosing cell is separately set in experiment
Blank control group and medium controls.
Comparative example 2
Growth inhibition effect of the Ferric Ammonium Citrate (FAC) to tumour cell
Cell strain and cell culture are same as Example 1：Experiment cell used includes osteosarcoma cell MG-63, MNNG/
HOS and U2OS.The condition of culture of all cells is：37 DEG C in carbon dioxide incubator, saturated humidity, carbon dioxide content be
5%, it is grown on containing 10% fetal calf serum, containing in 1% dual anti-DMEM culture mediums, MG-63 and MNNG/HOS are passed for every two days
In generation, is primary, and U2OS passages in every four days are primary, and centre changes the liquid once.
The cell in logarithmic phase growth is collected, is prepared into 5 × 104The single cell suspension of a/mL.Cell suspension is pressed per hole
100uL is inoculated in 96 well culture plates, after being cultivated for 24 hours in carbon dioxide incubator, discards original fluid.It is added containing difference
The culture medium of concentration Ferric Ammonium Citrate to be measured (0uM, 10uM, 20uM, 40uM, 80uM, 160uM, 320uM, 640uM, 1280uM),
Six holes are arranged in each concentration, cultivate respectively for 24 hours, 48h, 72h, effect of the observation drug to osteosarcoma cell.It is separately set in experiment
Non- dosing cell blank control group and medium controls.
Half-inhibition concentration of the CCK-8 methods detection to cell growth is respectively adopted in embodiment 1, comparative example 1, comparative example 2,
Specifically CCK-8 methods are：Cell discards former culture medium after drug-treated setting time, and 100uL is added per hole and contains 10%
The culture medium of CCK-8 solution, reacts 2h in carbon dioxide incubator.96 orifice plates are taken out, is measured and is inhaled with microplate reader at 450nm
Light value.Light absorption value and living cells quantity per hole is proportional, cell survival rate (%)=(drug-treated group light absorption value-sky
White control group light absorption value)/(cell controls group light absorption value-blank control group light absorption value) × 100%.
Three kinds of pharmaceutical composition of dihydroartemisinine and Ferric Ammonium Citrate, individual dihydroartemisinine pair osteosarcoma cell associations
With inhibiting effect comparison experimental result such as Fig. 1,2,3 show, growth inhibition effect of the Ferric Ammonium Citrate to MG-63 osteosarcoma cells
Experimental result it is as shown in Figure 4,5, 6.
Experimental result shows that dihydroartemisinine shows three-type-person's osteosarcoma cell line MG63, MNNG/HOS, U2OS
Concentration dependent and time-dependent inhibition effect.Ferric Ammonium Citrate to three-type-person's osteosarcoma cell line MG63, MNNG/HOS,
U2OS is without obvious inhibiting effect.And dihydroartemisinine is combined with Ferric Ammonium Citrate, can be reduced dihydroartemisinine and be played inhibition
The concentration of effect enhances the effect of the anti-osteosarcoma of dihydroartemisinine.As it can be seen that Ferric Ammonium Citrate can promote the anti-of dihydroartemisinine
The effect of osteosarcoma, the two synergy can reduce the dosage of dihydroartemisinine, while enhance the suppression of dihydroartemisinine again
Effect processed.
The foregoing is merely illustrative of the preferred embodiments of the present invention, is not intended to limit the invention, all essences in the present invention
All any modification, equivalent and improvement etc., should all be included in the protection scope of the present invention made by within refreshing and principle.
Claims (9)
1. a kind of antitumor medicine composition, which is characterized in that described pharmaceutical composition include at least one qinghaosu and its
Derivative, at least one iron preparation and ascorbic acid.
2. antitumor medicine composition as described in claim 1, which is characterized in that the qinghaosu and its derivative choosing are green
Artemisin, dihydroartemisinine, Artesunate, Artemtherin, qinghaosu ether.
3. antitumor medicine composition as described in claim 1, which is characterized in that the iron preparation is inorganic iron.
4. antitumor medicine composition as claimed in claim 3, which is characterized in that the iron preparation be selected from ferrous sulfate,
Ferrous fumarate, Ferric Ammonium Citrate, iron-dextrin, ferric oxide nanometer particle, carboxyl maltose iron, surpasses ferrous gluconate
Paramagnetic iron oxide.
5. antitumor medicine composition according to any one of claims 1-4, which is characterized in that the qinghaosu and its spread out
The molar ratio of biology, ascorbic acid and iron preparation is 1:100~1000:0.5~10.
6. antitumor medicine composition according to any one of claims 1-4, which is characterized in that further include that can pharmaceutically connect
The auxiliary material received.
7. antitumor medicine composition according to any one of claims 1-4, which is characterized in that described pharmaceutical composition by
At least one qinghaosu and its derivative, at least one iron preparation, ascorbic acid and pharmaceutically acceptable auxiliary material are made.
8. antitumor medicine composition is as the purposes for preparing antitumor drug as described in claim any one of 1-7.
9. the purposes of antitumor medicine composition as claimed in claim 8, which is characterized in that described pharmaceutical composition is being made
The purposes of standby liver-cancer medicine, liver-cancer medicine, colon cancer drug, oesophagus cancer drug, lung-cancer medicament, osteocarcinoma drug.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810226420.XA CN108403715B (en) | 2018-03-19 | 2018-03-19 | Anti-tumor pharmaceutical composition and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810226420.XA CN108403715B (en) | 2018-03-19 | 2018-03-19 | Anti-tumor pharmaceutical composition and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108403715A true CN108403715A (en) | 2018-08-17 |
| CN108403715B CN108403715B (en) | 2020-12-18 |
Family
ID=63132197
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810226420.XA Active CN108403715B (en) | 2018-03-19 | 2018-03-19 | Anti-tumor pharmaceutical composition and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403715B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109908137A (en) * | 2019-03-11 | 2019-06-21 | 江苏省人民医院（南京医科大学第一附属医院） | Application of artemisinin in medicine for killing breast cancer stem cells |
-
2018
- 2018-03-19 CN CN201810226420.XA patent/CN108403715B/en active Active
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109908137A (en) * | 2019-03-11 | 2019-06-21 | 江苏省人民医院（南京医科大学第一附属医院） | Application of artemisinin in medicine for killing breast cancer stem cells |
| CN109908137B (en) * | 2019-03-11 | 2022-02-18 | 江苏省人民医院（南京医科大学第一附属医院） | Application of artemisinin in medicine for killing breast cancer stem cells |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108403715B (en) | 2020-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103327986B (en) | Comprising the treatment using magnetic dipole stabilizing solutions or improve disease and enhance the method for performance | |
| EP1553935A2 (en) | Methods of using artemisinin-like compounds to prevent or delay the appearance of cancer | |
| IL143697A (en) | Use of biochemical substances for a composition for the prevention and treatment of health conditions caused by constriction of smooth muscle cells in organs of the human body | |
| KR101820977B1 (en) | Administraion of serine protease inhibitors to the stomach | |
| CN102008485A (en) | Losartan-containing compound preparation for treating hypertension | |
| CN104352513A (en) | Application of NADH (reduced form of nicotinamide-adenine dinucleotid) or salt thereof in preparing medicament or healthcare product for treating phenylketonuria | |
| US20090036527A1 (en) | Therapeutic Application Of Leonurine In Treating Cardiomyopathy | |
| US20070218126A1 (en) | Compositions and Methods for Reducing Inflammation and Pain Associated with Acidosis | |
| CN108403715A (en) | Antitumor medicine composition and application thereof | |
| CN108272820A (en) | Antitumor medicine composition and application thereof | |
| CN102008707A (en) | Quinapril-contained compound preparation for treating hypertension | |
| CN106420618B (en) | A kind of preparation method for the Norcantharidin micelle nano grain modified by Anti-CA Ⅸ | |
| CN102198195A (en) | Antioxidative medicinal composition | |
| CN108542905A (en) | Antitumor medicine composition and application thereof | |
| US20080160001A1 (en) | Antihypercholesterolemic Formulation with Less Side-Effects | |
| CN111329982A (en) | Novel application of bupleurum tenue granules in combination with chloroquine phosphate | |
| JP2008528640A (en) | Antitumor synergistic pharmaceutical composition of baicalein and baicalin | |
| US20050281904A1 (en) | Kefir extract as an anti-cancer agent | |
| US11844811B2 (en) | Methods and compositions for alleviating respiratory dysfunction | |
| CN112618569A (en) | Medicine for treating urothelial cancer | |
| CN106074502A (en) | Arteannuin and/or iron chelating agent are used as the application of parasite insecticide | |
| CN106038571B (en) | A kind of pharmaceutical composition and its application in preparation of anti-tumor drugs of the Gefitinib of targeted drug containing small molecule | |
| CN102573864A (en) | Method of treatment of liver disease | |
| US20100173014A1 (en) | Methods of making and using nano scale particles | |
| CN110123813A (en) | Application and drug of the heterocyclic compound that plant of Solanaceae is extracted in the drug of preparation treatment multiple sclerosis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20211223 Address after: 601d, 6th floor, Sanhang science and technology building, Northwest University of technology, 45 Gaoxin South 9th Road, high tech Zone community, Yuehai street, Nanshan District, Shenzhen, Guangdong 518000 Patentee after: Shenzhen cilisheng Technology Co.,Ltd. Address before: 518000 room 311, 3 / F, block r4-a, Virtual University Park, 019 Gaoxin South 4th Road, Yuehai street, Nanshan District, Shenzhen, Guangdong Patentee before: SHENZHEN HAICIKANG TECHNOLOGY Co.,Ltd. |